Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on December 16, 2010. The report details a material definitive agreement entered into by Emergent BioDefense Operations Lansing LLC, a wholly-owned subsidiary of Emergent, with Hollister-Stier Laboratories LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new supply agreement.
Material Changes and Agreement Details
On December 16, 2010, Emergent entered into a Supply Agreement with Hollister-Stier to continue filling services for BioThrax (Anthrax Vaccine Adsorbed) following the expiration of the prior agreement on December 31, 2010. Key terms include:
- Term: An initial five-year period commencing January 1, 2011.
- Renewals: Two additional automatic two-year renewal periods, triggered at Emergent's discretion.
- Volume Obligation: Emergent is obligated to utilize Hollister-Stier for 75% of its BioThrax filling requirements during the agreement term.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the operational commitment to the new supply agreement. No unusual items or contingencies were disclosed in this report.
Key Facts for Investor Verification
- Confirmation that Hollister-Stier will fulfill 75% of BioThrax filling needs starting January 1, 2011.
- Verification of the total potential contract duration (up to 9 years with renewals).
- Assessment of the financial impact of this agreement on future cost of goods sold, which is not detailed in this filing.